244 related articles for article (PubMed ID: 24690311)
1. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.
Matte I; Lane D; Boivin M; Rancourt C; Piché A
BMC Cancer; 2014 Apr; 14():234. PubMed ID: 24690311
[TBL] [Abstract][Full Text] [Related]
2. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
3. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Boivin M; Lane D; Piché A; Rancourt C
Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
[TBL] [Abstract][Full Text] [Related]
4. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
6. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
7. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
Bellail AC; Tse MC; Song JH; Phuphanich S; Olson JJ; Sun SY; Hao C
J Cell Mol Med; 2010 Jun; 14(6A):1303-17. PubMed ID: 19432816
[TBL] [Abstract][Full Text] [Related]
8. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2.
Martín-Pérez R; Niwa M; López-Rivas A
Apoptosis; 2012 Apr; 17(4):349-63. PubMed ID: 22072062
[TBL] [Abstract][Full Text] [Related]
9. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
10. α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway.
Yu W; Tiwary R; Li J; Park SK; Jia L; Xiong A; Simmons-Menchaca M; Sanders BG; Kline K
Mol Carcinog; 2010 Nov; 49(11):964-73. PubMed ID: 20886583
[TBL] [Abstract][Full Text] [Related]
11. The SCF
Roberts JZ; Holohan C; Sessler T; Fox J; Crawford N; Riley JS; Khawaja H; Majkut J; Evergren E; Humphreys LM; Ferris J; Higgins C; Espona-Fiedler M; Moynagh P; McDade SS; Longley DB
Cell Death Differ; 2020 Sep; 27(9):2726-2741. PubMed ID: 32313199
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.
Clarke P; Tyler KL
Apoptosis; 2007 Jan; 12(1):211-23. PubMed ID: 17136319
[TBL] [Abstract][Full Text] [Related]
13. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis.
Siegmund D; Hadwiger P; Pfizenmaier K; Vornlocher HP; Wajant H
Mol Med; 2002 Nov; 8(11):725-32. PubMed ID: 12520089
[TBL] [Abstract][Full Text] [Related]
15. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.
Duiker EW; van der Zee AG; de Graeff P; Boersma-van Ek W; Hollema H; de Bock GH; de Jong S; de Vries EG
Gynecol Oncol; 2010 Mar; 116(3):549-55. PubMed ID: 19959214
[TBL] [Abstract][Full Text] [Related]
16. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
17. Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.
Kavuri SM; Geserick P; Berg D; Dimitrova DP; Feoktistova M; Siegmund D; Gollnick H; Neumann M; Wajant H; Leverkus M
J Biol Chem; 2011 May; 286(19):16631-46. PubMed ID: 21454681
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
19. Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells.
Zhu ZC; Liu JW; Yang C; Li MJ; Wu RJ; Xiong ZQ
Cell Death Dis; 2019 Feb; 10(2):118. PubMed ID: 30742128
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
